<DOC>
	<DOC>NCT01244217</DOC>
	<brief_summary>Primary Objective: - To evaluate safety (4 weeks) Secondary Objectives: - To evaluate the long-term safety (12 weeks) - To evaluate the efficacy - To characterize the pharmacokinetic profile</brief_summary>
	<brief_title>Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)</brief_title>
	<detailed_description>The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<criteria>Inclusion criteria: Aged 6 months through 11 years Patients with perennial allergic rhinitis Exclusion criteria: Neither serum specific IgE antibody or skin reaction is positive for the antigen of perennial allergy. Nasal symptom score is 0 for either sneezing or nasal discharge, or sum of these two score is less than 3, or nasal congestion score is 4. Patients with vasomotor rhinitis or eosinophilic rhinitis. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>